智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

Market Overview - Uncertainty over tariff outlook suppresses rebound in US stocks, with major indices closing higher: Dow Jones up 0.28%, S&P 500 up 0.4%, and Nasdaq up 0.39% [1] - Nvidia shares rise over 3% post-earnings, while Best Buy falls over 7%, C3.ai surges nearly 21%, and Dell sees a post-market increase of over 5% [1] - Chinese concept stocks index rises over 1%, ending a seven-day decline, with notable gains in stocks like Aiyu Holdings up 7.81%, JD.com up 4.31%, and Xpeng up 3.98% [1] Corporate Actions - Huang Renxun plans to sell up to 6 million shares of Nvidia, valued at over $800 million, significantly exceeding previous sales [3] - Dell Technologies reports AI server orders exceeding expectations, with a bright revenue outlook [4] Domestic Developments - The Central Committee and State Council issue opinions to enhance the market-oriented allocation of resource and environmental factors, encouraging the expansion of pollutant discharge rights trading [5] - The launch of the Hongdao operating system marks a significant advancement in China's foundational software for intelligent robots, supporting the autonomy of domestic robot operating systems [5] Industry Insights - The Ministry of Commerce and other departments release key enterprises and projects for national cultural exports for 2025-2026 [6] - Zhejiang issues implementation opinions to promote the innovative development of intelligent computing cloud, aiming for a scale of 60 EFlops by 2027 [7] - The establishment of a pilot base for embodied intelligence by Yushun Technology and Hangzhou Data Group [9] Stock Market Trends - Recent analysis indicates a market recovery with major indices and stocks showing upward movement after a period of adjustment, with a focus on technology, finance, and new consumption sectors [11] - The feed industry sees price increases of 50-100 yuan per ton due to rising corn prices, with expectations of continued upward trends in corn prices [12] - The carbon neutrality initiative aims to establish a market-oriented trading system for carbon emissions, water usage, and pollutant discharge by 2027, enhancing market activity and price formation mechanisms [13] New Initiatives - Douyin Group establishes a short drama copyright center to enhance copyright management and support quality production [14] - Zhiyuan Robotics announces its humanoid robot has received multiple certifications, marking a significant achievement in safety and technology standards [15][16] Upcoming IPOs - Yingshi Innovation plans to issue shares on the Sci-Tech Innovation Board at a price of 47.27 yuan per share, requiring a minimum market value of 65,000 yuan for top-tier subscriptions [17] Company Announcements - Guangyang Co. terminates the acquisition of 100% equity in Yinjing Technology, leading to stock resumption [18] - Shuanglin Co. plans to raise no more than 1.5 billion yuan for the industrialization of roller screw and joint modules [18] - Yuntian Lifa's DeepEdge10 chip has achieved commercialization in robotics and servers [18]

Group 1 - The innovative drug sector in A-shares has shown a strong comeback, with multiple stocks experiencing significant price increases, including Shuyou Shen (20% increase) and Ruizhi Pharmaceutical (20% increase), indicating a bullish market sentiment [1] - The Hong Kong market also saw a rise, with WuXi AppTec increasing by 19.88% and several innovative drug ETFs in Hong Kong showing year-to-date gains exceeding 40%, outperforming similar products [1][2] - Analysts suggest that the domestic market is entering a concentrated listing period for innovative drugs, supported by comprehensive policy backing and improvements in commercial medical insurance, which are expected to enhance the commercialization process beyond market expectations [1][5] Group 2 - There is a noticeable divergence in the performance of various medical ETFs, with some experiencing significant inflows while others face substantial outflows, indicating mixed investor sentiment [2][3] - The top-performing innovative drug ETFs, such as ICBC Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, have seen net inflows of 2.43 billion and 2.31 billion respectively, while the E Fund CSI 300 Healthcare ETF has recorded the highest net outflow of 2.5 billion [3] - The medical sector is expected to show its best performance in three years by mid-2025, driven by policy optimization and AI industry empowerment, with a clear trend of performance and valuation recovery anticipated in the second half of the year [3] Group 3 - The innovative drug sector has rebounded significantly after a period of decline, with innovative drug ETFs showing substantial weekly gains, particularly in the lead-up to the ASCO annual meeting, which has heightened industry interest [4] - The upcoming ASCO meeting is expected to showcase numerous original research results from Chinese pharmaceutical companies, indicating a shift towards international innovation in drug development [4][5] - Recent approvals of six domestic innovative drugs in May across critical treatment areas such as diabetes and tumors have injected strong momentum into the pharmaceutical industry [5]

Macro Dynamics - The Chinese Ministry of Commerce urges the U.S. to completely eliminate unilateral tariffs, emphasizing that trade wars have no winners and protectionism leads to negative outcomes [1] - The Chinese Ministry of Foreign Affairs firmly opposes the U.S. decision to unjustly cancel Chinese student visas, stating it harms the legitimate rights of Chinese students and disrupts normal cultural exchanges between the two countries [2] Market Data - On May 29, the A-share market saw the ChiNext Index rise by 1.37%, with significant gains in digital currency and EDA concepts, as well as autonomous driving and innovative drug sectors [7] - The total market turnover reached 1.2 trillion yuan, an increase from the previous day's 1 trillion yuan, with over 4,400 stocks rising [7] - As of May 28, the total margin balance in the two markets increased by 2.95 billion yuan, with the Shanghai Stock Exchange's margin balance at 909.99 billion yuan and the Shenzhen Stock Exchange's at 883.23 billion yuan [8] Company Dynamics - Tesla's CEO Elon Musk announced that the Model Y autonomous driving vehicle will be delivered to customers in June, with successful testing on public roads in Austin [10] - Ideal Auto reported a total revenue of 25.9 billion yuan for Q1 2025, a year-on-year increase of 1.1%, and a net profit of 647 million yuan, up 9.4% year-on-year, with total vehicle deliveries of 92,900 units, reflecting a 15.5% increase [12]

Core Viewpoint - The company, Shuyou Shen, has announced that there is significant uncertainty regarding whether its drug "STSP-0601" will enter the priority review process after the public notice period ends [1] Group 1: Stock Performance - The company's stock has experienced a significant abnormal fluctuation, with a cumulative price deviation of over 100% in the last ten trading days and over 200% in the last thirty trading days [1] Group 2: Drug Approval Process - The drug "STSP-0601," developed by the company's subsidiary Jiangsu Beijitai Biotechnology Co., is currently in the public notice period, which will end on June 3, 2025 [1] - There is high market attention on the information regarding the drug's application for priority review as published on the National Medical Products Administration (NMPA) website [1] - The company emphasizes that there are many uncertainties regarding whether the drug will proceed to the priority review process after the public notice period [1]

证券代码：300204 证券简称：舒泰神 公告编号：2025-037 舒泰神（北京）生物制药股份有限公司 关于股票交易严重异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、舒泰神（北京）生物制药股份有限公司股票交易连续十个交易日（2025 年05月16日至2025年05月29日）收盘价格涨幅偏离值累计超过100%；连续三十 个交易日（2025年04月15日至2025年05月29日）收盘价格涨幅偏离值累计超过 200%；根据《深圳证券交易所交易规则》等相关规定，属于股票交易严重异常 波动的情况。 2、经公司董事会核实，截至本公告披露日，公司、控股股东和实际控制人 不存在关于本公司的应披露而未披露的重大事项，在股票异常波动期间不存在买 卖公司股票的行为。 3、公司关注到近期市场对国家药品监督管理局药品审评中心（NMPA）网 站信息公开栏目关于"拟优先审评品种公示"栏中公司控股子公司江苏贝捷泰生 物科技有限公司申请的"注射用 STSP-0601"相关信息关注度较高；该药品正处 于公示期内，公示截止日期为 2025 年 06 月 03 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-036 舒泰神（北京）生物制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）于近期取得了 北京市药品监督管理局（以下简称"市药监局"）换发的药品生产许可证，同意 公司"北京市北京经济技术开发区经海二路 36 号"地址项下的"原液四车间： 原液四车间生产线、冻干车间：冻干粉针生产线"接受江苏贝捷泰生物科技有限 公司的注射用 STSP-0601 的委托生产。《药品生产许可证》有效期至 2025 年 12 月 07 日，分类码增加 Cs（仅限注册申报使用）。本次委托生产品种待持有人取 得药品批准证明文件并通过药品 GMP 符合性检查后方可正式生产。变更后的《药 品生产许可证》具体内容如下： 一、《药品生产许可证》主要情况 企业名称：舒泰神（北京）生物制药股份有限公司 社会信用代码：911100007423131451 注册地址：北京市北京经济技术开发区经海二路 36 号 法定代表人：周志文 企业负责人： ...

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

Market Overview - The A-share market saw a strong rise with the three major indices up, including the Shanghai Composite Index increasing by 0.7% to 3363.45 points, the Shenzhen Component rising by 1.24% to 10127.2 points, and the ChiNext Index up by 1.37% to 2012.55 points. The North Star 50 Index surged by 2.73% [1] - Total trading volume in the Shanghai, Shenzhen, and North exchanges reached 121.36 billion yuan, an increase of nearly 18 billion yuan compared to the previous day [1] Semiconductor Sector - The semiconductor sector experienced a significant rally, with stocks like GCL-Poly and Guangliwei both hitting the 20% limit up. Other notable performers included Huada Jiutian, which rose nearly 15%, and Taiji Co., which increased over 9% [5][6] - Reports indicated that the U.S. government is requesting local companies to stop exporting software related to semiconductor design technology to China, affecting major companies in the Electronic Design Automation (EDA) market [7] Innovative Drug Sector - The innovative drug concept saw a substantial increase, with stocks such as Ruizhi Pharmaceutical, Yifang Bio, and Shutaishen all hitting the 20% limit up. Changshan Pharmaceutical rose over 15%, reaching new highs [9][11] - Shutaishen announced that it received approval for clinical trials of its STSA-1002 injection for acute respiratory distress syndrome (ARDS), marking a significant step in its drug development [12] Data Element Sector - The data element concept showed strong performance, with stocks like Lakala, Xiongdi Technology, and Tianyang Technology all hitting the 20% limit up. Youbuxun rose over 14% [15][16] - The National Data Bureau announced the launch of the "Data Element ×" competition aimed at promoting the use of public and enterprise data, which is expected to enhance the economic and social development through better data application [17]

Market Overview - A-shares experienced a rebound on May 29, with the Shanghai Composite Index rising by 0.72%, the Shenzhen Component Index increasing by 1.12%, and the ChiNext Index up by 1.16% [1][2]. Sector Performance - The digital currency and fintech sectors saw significant gains, while sectors such as gold and jewelry, air transportation, and food processing faced declines [2][3]. - Notable sector performances included: - Digital currency: +6.56% - Fintech: +5.48% - Innovative drugs: +20% for Shuyou Shen [3][7]. Notable Stocks - In the Hong Kong market, the Hang Seng Technology Index rose by 1.64%, with stocks like Xpeng Motors (+6.08%), Meituan (+4.64%), and Trip.com (+3.81%) leading the gains [4][5]. - Digital currency stocks surged, with companies like Sifang Jingchuang, Xiongdai Technology, and Tianyang Technology hitting the daily limit of 20% [5]. - Innovative drug stocks also performed well, with Shuyou Shen reaching a three-year high [7][9]. Regulatory Developments - The U.S. Congress is advancing two key stablecoin legislations, while Hong Kong's Legislative Council has passed a stablecoin bill, establishing a licensing system for fiat-backed stablecoin issuers [10].